Legend Biotech Corporation (LEGN) NASDAQ

35.69

+10.1761(+39.89%)

Updated at June 02 02:58PM

Currency In USD

Key Executives

Name	Title	Year Born
Ying Huang	Chief Executive Officer & Director	1973
Guowei Fang	President of Research & Development	N/A
Carlos Santos	Chief Financial Officer	1972
Joanne Choi	Senior Manager of Investor Relations	N/A
Surabhi Verma	Manager of Investor Relations & Corporate Communications	N/A
James Pepin	General Counsel	N/A
Ananda Elizabeth Martin	Global Compliance Officer	1974
Jessie Yeung	Vice President of Finance, Investor & Public Relations	1985
Alan Bash	President of CARVYKTI®	1972
Birk Vanderweeen	Senior Vice President of Global Manufacturing & Supply	N/A

Name

Title

Pay

Year Born

Ying Huang

Chief Executive Officer & Director

1973

Guowei Fang

President of Research & Development

N/A

Carlos Santos

Chief Financial Officer

1972

Joanne Choi

Senior Manager of Investor Relations

N/A

Surabhi Verma

Manager of Investor Relations & Corporate Communications

N/A

James Pepin

General Counsel

N/A

Ananda Elizabeth Martin

Global Compliance Officer

1974

Jessie Yeung

Vice President of Finance, Investor & Public Relations

1985

Alan Bash

President of CARVYKTI®

1972

Birk Vanderweeen

Senior Vice President of Global Manufacturing & Supply

N/A

Description

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.